|
IL308456A
(en)
|
2005-04-08 |
2024-01-01 |
Wyeth Llc |
A multivalent pneumomuroral protein-polysaccharide conjugate preparation
|
|
US20070184072A1
(en)
|
2005-04-08 |
2007-08-09 |
Wyeth |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
|
HUE045482T2
(hu)
|
2005-06-27 |
2019-12-30 |
Glaxosmithkline Biologicals Sa |
Immunogén készítmény
|
|
GB0607088D0
(en)
*
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
JP5792920B2
(ja)
|
2005-12-22 |
2015-10-14 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
ワクチン
|
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
|
US8808707B1
(en)
|
2006-05-08 |
2014-08-19 |
Wyeth Llc |
Pneumococcal dosing regimen
|
|
GB0822634D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Meningitis vaccines
|
|
WO2010080486A2
(en)
|
2008-12-18 |
2010-07-15 |
Wyeth Llc |
Method for controlling streptococcus pneumoniae serotype 19a polysaccharide molecular weight
|
|
EP2385981B1
(en)
*
|
2008-12-18 |
2019-09-04 |
Wyeth LLC |
Method for controlling streptococcus pneumoniae polysaccharide molecular weight using carbon
|
|
CN104548082A
(zh)
|
2009-03-24 |
2015-04-29 |
诺华股份有限公司 |
为脑膜炎球菌因子h结合蛋白添加佐剂
|
|
EP3017826A1
(en)
|
2009-03-24 |
2016-05-11 |
Novartis AG |
Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
|
|
DK2424562T3
(en)
|
2009-04-30 |
2015-12-07 |
Coley Pharm Group Inc |
Pneumococcal vaccine and uses thereof
|
|
GB201003922D0
(en)
*
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
|
EP3626263A1
(en)
|
2010-06-04 |
2020-03-25 |
Wyeth LLC |
Vaccine formulations
|
|
WO2011161653A1
(en)
|
2010-06-25 |
2011-12-29 |
Novartis Ag |
Combinations of meningococcal factor h binding proteins
|
|
CN103533954B
(zh)
|
2011-03-02 |
2015-09-09 |
诺华股份有限公司 |
含较低剂量的抗原和/或佐剂的联合疫苗
|
|
EP2797624A1
(en)
|
2011-12-29 |
2014-11-05 |
Novartis AG |
Adjuvanted combinations of meningococcal factor h binding proteins
|
|
WO2013131983A1
(en)
|
2012-03-07 |
2013-09-12 |
Novartis Ag |
Adjuvanted formulations of streptococcus pneumoniae antigens
|
|
EP2822584A1
(en)
|
2012-03-08 |
2015-01-14 |
Novartis AG |
Combination vaccines with tlr4 agonists
|
|
KR102057217B1
(ko)
|
2012-06-20 |
2020-01-22 |
에스케이바이오사이언스 주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
|
BR112015005056A2
(pt)
|
2012-09-06 |
2017-11-21 |
Novartis Ag |
vacinas de combinação com sorogrupo b meningococcus e d/t/p
|
|
GB201218660D0
(en)
|
2012-10-17 |
2012-11-28 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
|
KR20140075196A
(ko)
*
|
2012-12-11 |
2014-06-19 |
에스케이케미칼주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
|
JP2016502994A
(ja)
|
2012-12-18 |
2016-02-01 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
ジフテリア及び／又は破傷風から防御するためのコンジュゲート
|
|
FI3583947T3
(fi)
|
2014-01-21 |
2023-10-12 |
Pfizer |
Streptococcus pneumoniaen kapselipolysakkaridit ja niiden konjugaatit
|
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
BR112016015835B1
(pt)
|
2014-01-21 |
2023-12-26 |
Pfizer Inc |
Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae
|
|
IL312327B2
(en)
*
|
2014-01-21 |
2026-02-01 |
Pfizer |
Immunogenic preparations comprising conjugated capsular saccharide antigens and their uses
|
|
CN103893751B
(zh)
*
|
2014-03-26 |
2016-04-20 |
天津康希诺生物技术有限公司 |
一种肺炎球菌多糖蛋白缀合疫苗及其制备方法
|
|
PL3244917T3
(pl)
|
2015-01-15 |
2023-07-17 |
Pfizer Inc. |
Kompozycje immunogenne do zastosowania w szczepionkach przeciwko pneumokokom
|
|
KR102143534B1
(ko)
|
2015-05-04 |
2020-08-12 |
화이자 인코포레이티드 |
B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
|
|
KR20250058066A
(ko)
|
2015-07-21 |
2025-04-29 |
화이자 인코포레이티드 |
접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
|
|
US10786561B2
(en)
|
2015-11-20 |
2020-09-29 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
|
GB201610599D0
(en)
|
2016-06-17 |
2016-08-03 |
Glaxosmithkline Biologicals Sa |
Immunogenic Composition
|
|
EP3493837B1
(en)
|
2016-08-05 |
2022-08-31 |
Sanofi Pasteur, Inc. |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
|
US11224652B2
(en)
|
2016-08-05 |
2022-01-18 |
Sanofi Pasteur Inc. |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
|
US10751402B2
(en)
|
2016-11-09 |
2020-08-25 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|
|
IL267709B2
(en)
|
2016-12-30 |
2025-04-01 |
Vaxcyte Inc |
Polypeptide-antigen conjugates with unnatural amino acids
|
|
US11951165B2
(en)
|
2016-12-30 |
2024-04-09 |
Vaxcyte, Inc. |
Conjugated vaccine carrier proteins
|
|
BR112019014833A2
(pt)
|
2017-01-20 |
2020-04-14 |
Pfizer |
composições imunogênicas para uso em vacinas pneumococais
|
|
WO2018144439A1
(en)
|
2017-01-31 |
2018-08-09 |
Merck Sharp & Dohme Corp. |
Methods for making polysaccharide-protein conjugates
|
|
JP7680185B2
(ja)
*
|
2017-02-24 |
2025-05-20 |
メルク・シャープ・アンド・ドーム・エルエルシー |
肺炎連鎖球菌多糖－タンパク質コンジュゲートの免疫原性の増強
|
|
MX2019014829A
(es)
|
2017-06-10 |
2020-08-17 |
Inventprise Llc |
Vacunas de conjugado multivalente con polisacáridos de conjugado bivalente o multivalente que proporcionan inmunogenicidad y avidez mejoradas.
|
|
US10729763B2
(en)
|
2017-06-10 |
2020-08-04 |
Inventprise, Llc |
Mixtures of polysaccharide-protein pegylated compounds
|
|
US11395849B2
(en)
|
2017-09-07 |
2022-07-26 |
Merck Sharp & Dohme Llc |
Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
|
|
HUE068482T2
(hu)
|
2017-09-07 |
2025-01-28 |
Merck Sharp & Dohme Llc |
Pneumococcus-poliszacharidok és azok felhasználása immunogén poliszacharid-hordozóprotein konjugátumokban
|
|
CN111065387B
(zh)
|
2017-09-07 |
2023-08-25 |
默沙东有限责任公司 |
肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
|
|
EP3720483B1
(en)
|
2017-12-06 |
2025-11-19 |
Merck Sharp & Dohme LLC |
Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
|
|
GB201721576D0
(en)
|
2017-12-21 |
2018-02-07 |
Glaxosmithkline Biologicals Sa |
Hla antigens and glycoconjugates thereof
|
|
WO2019152921A1
(en)
|
2018-02-05 |
2019-08-08 |
Sanofi Pasteur Inc. |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
|
BR112020015696A2
(pt)
|
2018-02-05 |
2020-12-08 |
Sanofi Pasteur, Inc. |
Composição de conjugado polissacarídeo-proteína pneumocócico multivalente
|
|
EP3765516A2
(en)
*
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
EP4483896A3
(en)
|
2018-07-04 |
2025-04-02 |
Vaxcyte, Inc. |
Improvements in immunogenic conjugates
|
|
WO2020010000A1
(en)
|
2018-07-04 |
2020-01-09 |
Sutrovax, Inc. |
Improved methods for the preparation of immunogenic conjugates
|
|
WO2020010016A1
(en)
|
2018-07-04 |
2020-01-09 |
Sutrovax, Inc. |
Self-adjuvanted immunogenic conjugates
|
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
|
JP7551618B2
(ja)
|
2018-12-12 |
2024-09-17 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
Ｏ－結合型グリコシル化のための修飾キャリアタンパク質
|
|
US20220016229A1
(en)
|
2018-12-12 |
2022-01-20 |
Pfizer Inc. |
Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
|
|
EP3897705A2
(en)
|
2018-12-19 |
2021-10-27 |
Merck Sharp & Dohme Corp. |
Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
|
|
US20220184199A1
(en)
|
2019-04-10 |
2022-06-16 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
|
EP3757217A1
(en)
|
2019-06-27 |
2020-12-30 |
GlaxoSmithKline Biologicals S.A. |
Methods for protein purification
|
|
JP2022542316A
(ja)
|
2019-07-31 |
2022-09-30 |
サノフィ パスツール インコーポレイテッド |
多価肺炎球菌多糖体－タンパク質コンジュゲート組成物およびその使用方法
|
|
EP3777884A1
(en)
|
2019-08-15 |
2021-02-17 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic composition
|
|
JOP20200214A1
(ar)
|
2019-09-03 |
2021-03-03 |
Serum Institute Of India Pvt Ltd |
تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
|
|
US12473379B2
(en)
*
|
2019-09-06 |
2025-11-18 |
Serum Institute Of India Private Limited |
Method for obtaining purified bacterial polysaccharides
|
|
AU2020375214B2
(en)
|
2019-11-01 |
2024-02-08 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
|
KR20220143910A
(ko)
|
2020-02-23 |
2022-10-25 |
화이자 인코포레이티드 |
에스케리키아 콜라이 조성물 및 그의 방법
|
|
EP3900739A1
(en)
|
2020-04-21 |
2021-10-27 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein
|
|
WO2021229604A1
(en)
*
|
2020-05-14 |
2021-11-18 |
Serum Institute Of India Private Limited |
Methods for simultaneous fragmentation and purification of bacterial polysaccharides
|
|
EP3919076A1
(en)
|
2020-06-02 |
2021-12-08 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Synthetic oligosaccharide vaccines against streptococcus pneumoniae with microparticle adjuvant formulations
|
|
US20230226175A1
(en)
|
2020-06-25 |
2023-07-20 |
Glaxosmithkline Biologicals Sa |
Modified exotoxin a proteins
|
|
US12053515B2
(en)
|
2020-08-10 |
2024-08-06 |
Inventprise, Inc. |
Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
|
|
EP4203995A1
(en)
|
2020-08-26 |
2023-07-05 |
Pfizer Inc. |
Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
|
|
US12138302B2
(en)
|
2020-10-27 |
2024-11-12 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
|
MX2023004912A
(es)
|
2020-10-27 |
2023-05-16 |
Pfizer |
Composiciones de escherichia coli y metodos de las mismas.
|
|
CA3200602A1
(en)
|
2020-11-04 |
2022-05-12 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
|
US20230405137A1
(en)
|
2020-11-10 |
2023-12-21 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
US12357681B2
(en)
|
2020-12-23 |
2025-07-15 |
Pfizer Inc. |
E. coli FimH mutants and uses thereof
|
|
KR102610292B1
(ko)
*
|
2021-02-10 |
2023-12-04 |
에스케이바이오사이언스(주) |
스트랩토코커스 뉴모니애 다당류와 운반체 단백질의 접합체 제조 방법
|
|
CA3218544A1
(en)
|
2021-05-03 |
2022-11-10 |
Pfizer Inc. |
Vaccination against bacterial and betacoronavirus infections
|
|
WO2022234416A1
(en)
|
2021-05-03 |
2022-11-10 |
Pfizer Inc. |
Vaccination against pneumoccocal and covid-19 infections
|
|
JP7714690B2
(ja)
|
2021-05-28 |
2025-07-29 |
ファイザー・インク |
コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
|
|
CA3221075A1
(en)
|
2021-05-28 |
2022-12-01 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
EP4452308A1
(en)
|
2021-12-22 |
2024-10-30 |
GlaxoSmithKline Biologicals S.A. |
Vaccine
|
|
JP2025508749A
(ja)
|
2022-01-13 |
2025-04-10 |
ファイザー・インク |
コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
|
|
WO2023192997A2
(en)
*
|
2022-03-31 |
2023-10-05 |
The Children's Medical Center Corporation |
Immunogenic compositions for b-cell recall response to a polysaccharide antigen
|
|
US20250312433A1
(en)
|
2022-05-11 |
2025-10-09 |
Pfizer Inc. |
Process for Producing of Vaccine Formulations With Preservatives
|
|
US20260130987A1
(en)
|
2022-10-19 |
2026-05-14 |
Pfizer Inc. |
Vaccination against pneumoccocal and covid-19 infections
|
|
WO2024110827A1
(en)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Methods for preparing conjugated capsular saccharide antigens and uses thereof
|
|
EP4622665A2
(en)
|
2022-11-22 |
2025-10-01 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
CN120513083A
(zh)
|
2022-12-01 |
2025-08-19 |
辉瑞大药厂 |
肺炎链球菌缀合物疫苗制剂
|
|
WO2024166008A1
(en)
|
2023-02-10 |
2024-08-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
GB202302579D0
(en)
|
2023-02-23 |
2023-04-12 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
|
AU2024246082A1
(en)
|
2023-03-30 |
2025-10-16 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
PE20252779A1
(es)
|
2023-04-14 |
2025-12-22 |
Pfizer |
Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos
|
|
WO2024224266A1
(en)
|
2023-04-24 |
2024-10-31 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
CN121263203A
(zh)
|
2023-05-19 |
2026-01-02 |
葛兰素史克生物有限公司 |
诱导对呼吸道合胞病毒和肺炎链球菌感染的免疫反应的方法
|
|
TW202527906A
(zh)
|
2023-09-14 |
2025-07-16 |
美商輝瑞股份有限公司 |
包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途
|
|
WO2025133971A1
(en)
|
2023-12-23 |
2025-06-26 |
Pfizer Inc. |
Improved methods for producing bacterial capsular saccharide glycoconjugates
|
|
US20250255948A1
(en)
|
2024-02-14 |
2025-08-14 |
Merck Sharp & Dohme Llc |
Pneumococcal conjugate vaccines and methods of use thereof
|
|
WO2025186705A2
(en)
|
2024-03-06 |
2025-09-12 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
TW202602467A
(zh)
|
2024-03-11 |
2026-01-16 |
美商輝瑞股份有限公司 |
包含經共軛之大腸桿菌糖的免疫原性組成物及其用途
|
|
WO2025219904A1
(en)
|
2024-04-19 |
2025-10-23 |
Pfizer Inc. |
Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
|